Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

Rhea-AI Summary

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced its participation in the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. CEO Daniel J. Hicklin, Ph.D., will present an overview of the company on-demand starting January 10 at 7 a.m. EST. Werewolf is focused on developing conditionally activated therapeutics that enhance the immune system for cancer treatment, utilizing its proprietary PREDATOR™ platform. The company's lead candidates, WTX-124 and WTX-330, target tumor microenvironments while minimizing peripheral activation.

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the H.C. Wainwright Bioconnect Conference, taking place virtually from January 10-13, 2022.

Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company, which will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Monday, January 10, 2022. A link to the archived webcast will be available at https://investors.werewolftx.com/news-and-events/events.

About Werewolf Therapeutics:
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

Investor Contact:
Jonathan M. Nugent
Stern IR
212.698.8698
jonathan.nugent@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

When is the H.C. Wainwright Bioconnect Conference for Werewolf Therapeutics?

The conference will take place virtually from January 10-13, 2022.

Who will present at the H.C. Wainwright Conference for Werewolf Therapeutics?

Daniel J. Hicklin, Ph.D., the CEO, will provide an overview of the company.

What are the main therapeutic platforms of Werewolf Therapeutics?

Werewolf uses the PREDATOR™ platform to develop conditionally activated therapeutics for cancer treatment.

What are the lead product candidates of Werewolf Therapeutics?

The lead candidates are WTX-124 and WTX-330, targeting solid tumors.

What is the goal of Werewolf's INDUKINE™ molecules?

The goal is to activate selectively in the tumor microenvironment while remaining inactive in peripheral tissues.